Welcome to our dedicated page for EASTMAN CHEMICAL CO SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EASTMAN CHEMICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EASTMAN CHEMICAL CO's regulatory disclosures and financial reporting.
Holder Julie Fasone reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Julie Fasone Holder received 408 Phantom Stock Units as a compensation award. These units are credited under the Directors' Deferred Compensation Plan, with each unit valued like one share of Eastman common stock but payable only in cash after she leaves the board.
This grant arose from the automatic deferral of a portion of her annual director retainer that would otherwise have been paid in cash, and it also reflects dividend equivalents that are reinvested into additional Phantom Stock Units. Following this award, she now holds a total of 15,051 Phantom Stock Units.
SLAGER DONALD W reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company director Donald W. Slager received a compensation grant of 408 Phantom Stock Units. These units were credited under the Directors' Deferred Compensation Plan at no purchase price and each unit tracks the value of one share of common stock.
The award represents an automatic deferral of a portion of the director’s annual cash retainer, with amounts payable only in cash after his service as a director ends. Following this grant, Slager holds a total of 1,699 Phantom Stock Units, including units from prior awards and dividend equivalents reinvested in additional units.
HORNBAKER RENEE J reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company director Renee J. Hornbaker received an award of 408 Phantom Stock Units tied to the value of the company’s common stock. These units were credited under the Directors' Deferred Compensation Plan as an automatic deferral of a portion of her annual retainer fees.
Each Phantom Stock Unit is payable only in cash after she terminates service as a director and includes dividend equivalents reinvested into additional units. After this grant, she holds a total of 51,107 Phantom Stock Units.
Mink Kim Ann reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Kim Ann Mink received a grant of 408 Phantom Stock Units on April 8, 2026. These units track the value of one share of common stock each but are payable only in cash after her service as a director ends. The grant represents an automatic deferral of a portion of her annual cash retainer fees and includes dividend equivalents reinvested in additional units. Following this award, she holds a total of 15,653 Phantom Stock Units credited under the Directors' Deferred Compensation Plan.
Eastman Chemical Co — Schedule 13G/A (Amendment No. 17)
The Vanguard Group reports no beneficial ownership of Eastman Chemical Co. common stock, listing 0 shares and 0% of the class. The filing explains that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report separately in reliance on SEC Release No. 34-39538.
Eastman Chemical Company is asking stockholders to vote at its virtual 2026 Annual Meeting on May 7, 2026. Proposals include electing eleven directors for one-year terms, ratifying PricewaterhouseCoopers LLP as auditor for 2026, an advisory "Say on Pay" vote on executive compensation, approval of the 2026 Omnibus Stock Compensation Plan, and an advisory vote on a stockholder proposal to lower the threshold for calling special meetings to 10%, which the Board opposes.
Eastman highlights its innovation-driven, sustainability-focused growth strategy and reports 2025 results of $8.8 billion in sales, $930 million adjusted EBIT, $474 million net earnings, diluted EPS of $4.10, and adjusted diluted EPS of $5.42. The company generated $970 million in net cash from operating activities and returned approximately $500 million to stockholders through dividends and share repurchases.
The Board emphasizes succession planning, board refreshment, and governance. Ten of eleven nominees are independent, average tenure is 9.7 years, and the Board recorded 99% average attendance at 34 Board and Committee meetings in 2025. Independent committees oversee audit, compensation, governance, finance, and environmental, safety, and sustainability matters, with strong focus on risk management, human capital, and long-term sustainability initiatives.
Holt Adrian James reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical senior vice president and chief human resources officer Adrian James Holt received new equity awards. On February 24, 2026, he was granted 32,116 employee stock options and 4,419 restricted stock units at a grant price of $0.00 per unit as compensation.
One-third of the options become exercisable on February 24, 2027, February 24, 2028, and February 24, 2029. Each restricted stock unit represents the right to receive one share of common stock and will vest and pay out in unrestricted shares on February 24, 2029, subject to continued employment.
Eastman Chemical’s Controller & CAO, Michelle Renee Stewart, reported equity awards consisting of stock options and restricted stock units. She was granted 11,075 employee stock options at an exercise price of $0.00 per option and 1,524 restricted stock units, all held as direct ownership.
According to the award terms, one-third of the options become exercisable on each of February 24, 2027, February 24, 2028, and February 24, 2029. Each restricted stock unit represents a contingent right to receive one share of Eastman Chemical common stock. The restricted stock units will vest and pay out in unrestricted shares on the third anniversary of the grant date, February 24, 2029, subject to continued employment.
McAlindon Julie A. reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical senior vice president Julie A. McAlindon received new equity awards on February 24, 2026. She was granted 24,364 employee stock options, which become exercisable in three equal parts on February 24, 2027, February 24, 2028, and February 24, 2029.
She was also awarded 3,352 restricted stock units, with each unit representing the right to receive one share of common stock. These units will vest and pay out in unrestricted shares on February 24, 2029, subject to her continued employment.